Kuros Biosciences AG - Company Profile
Powered by 
All the sales intelligence you need on Kuros Biosciences AG in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Kuros Biosciences AG fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Kuros Biosciences AG.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Kuros Biosciences AG (Kuros Biosciences) is a medical technology company. It is focused on the development of innovative products for tissue repair and bone regeneration. The company’s product portfolio includes MagnetOs, an advanced bone graft technology that stimulates bone growth, even in soft tissues, by enhancing the body's immune response, particularly pro-healing M2 macrophages. The technology behind MagnetOs, called osteoimmunology, activates the immune system to stimulate stem cells and promote healing. MagnetOs is available in multiple forms, including Granules, Putty, Easypack Putty, and Flex Matrix, to meet diverse perioperative clinical needs. Kuros Biosciences is headquartered in Schlieren, Zurich, Switzerland.
Headquarters
Switzerland
Address
Wagistrasse 25, Schlieren, Zurich, 8952
Website
kurosbio.com
Telephone
41 44 7334747
No of Employees
178
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
KURN (SWF)
Revenue (2024)
$146.1M
71.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
152.8%
(2024 vs 2023)
Market Cap*
$1.1B
Net Profit Margin (2024)
XYZ
130.8%
(2024 vs 2023)
* As of and is in US$
Kuros Biosciences AG premium industry data and analytics
Products and Services
| Products |
|---|
| MagnetOs: |
| Granules |
| Putty |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In January, Kuros Biosciences USA signed an agreement with Medtronic to create new opportunities in the US spine market. |
| 2024 | Others | In November, the company announced its strategic expansion into the extremities markets. |
| 2024 | Regulatory Approval | In January, the company received US FDA 510(k) clearance for MagnetOs Granules for interbody use and regulatory clearance for MagnetOs Granules and MagnetOs Putty in New Zealand. |
Competitor Comparison
| Key Parameters | Kuros Biosciences AG | Amgen Inc | Orthofix Medical Inc | Medartis Holding AG | Exactech Inc |
|---|---|---|---|---|---|
| Headquarters | Switzerland | United States of America | United States of America | Switzerland | United States of America |
| City | Schlieren | Thousand Oaks | Lewisville | Basel | Gainesville |
| State/Province | Zurich | California | Texas | - | Florida |
| No. of Employees | 178 | 31,500 | 1,605 | 1,400 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Chris Fair | Chief Executive Officer; Director | Executive Board | 2023 | 56 |
| Clemens van Blitterswijk, Ph.D. | Director | Executive Board | 2018 | 67 |
| Daniel Geiger | Chief Financial Officer | Senior Management | 2023 | 55 |
| I.V. Hall | Chief Operating Officer | Senior Management | 2026 | - |
| John Griffin | Chief Business Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer